UK Markets closed

Cyteir Therapeutics, Inc. (CYT)

NasdaqGS - NasdaqGS Real-time price. Currency in USD
Add to watchlist
1.9900+0.2200 (+12.43%)
As of 12:36PM EDT. Market open.
Currency in USD

Valuation measures4

Market cap (intra-day) N/A
Enterprise value N/A
Trailing P/E N/A
Forward P/E N/A
PEG ratio (5-yr expected) N/A
Price/sales (ttm)N/A
Price/book (mrq)N/A
Enterprise value/revenue N/A
Enterprise value/EBITDA N/A

Trading information

Stock price history

Beta (5Y monthly) N/A
52-week change 3N/A
S&P500 52-week change 3N/A
52-week high 323.1000
52-week low 31.5550
50-day moving average 33.2611
200-day moving average 311.0297

Share statistics

Avg vol (3-month) 3202.27k
Avg vol (10-day) 3474.48k
Shares outstanding 535.37M
Implied shares outstanding 6N/A
Float 810.16M
% held by insiders 111.42%
% held by institutions 183.89%
Shares short (28 Apr 2022) 42.23M
Short ratio (28 Apr 2022) 426.07
Short % of float (28 Apr 2022) 411.58%
Short % of shares outstanding (28 Apr 2022) 46.29%
Shares short (prior month 30 Mar 2022) 42.05M

Dividends & splits

Forward annual dividend rate 4N/A
Forward annual dividend yield 4N/A
Trailing annual dividend rate 3N/A
Trailing annual dividend yield 3N/A
5-year average dividend yield 4N/A
Payout ratio 40.00%
Dividend date 3N/A
Ex-dividend date 4N/A
Last split factor 2N/A
Last split date 3N/A

Financial highlights

Fiscal year

Fiscal year ends 30 Dec 2021
Most-recent quarter (mrq)30 Dec 2021

Profitability

Profit margin 0.00%
Operating margin (ttm)0.00%

Management effectiveness

Return on assets (ttm)-25.26%
Return on equity (ttm)-42.84%

Income statement

Revenue (ttm)N/A
Revenue per share (ttm)N/A
Quarterly revenue growth (yoy)N/A
Gross profit (ttm)N/A
EBITDA -41.78M
Net income avi to common (ttm)-42.13M
Diluted EPS (ttm)-3.2040
Quarterly earnings growth (yoy)N/A

Balance sheet

Total cash (mrq)189.72M
Total cash per share (mrq)5.38
Total debt (mrq)N/A
Total debt/equity (mrq)N/A
Current ratio (mrq)25.71
Book value per share (mrq)5.64

Cash flow statement

Operating cash flow (ttm)-36.03M
Levered free cash flow (ttm)-21.44M